Predictors of statin adherence

Current Cardiology Reports

Volumn 13, Issue 6, 2011, Pages 553-558

  Mauskop, Alexander ^a   Borden, William B ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Adherence; Cardiovascular disease; Coronary artery disease; Health system factors; Patient factors; Physician factors; Socioeconomic; Statin

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; CORONARY ARTERY ATHEROSCLEROSIS; DOCTOR PATIENT RELATION; DRUG COST; DRUG MECHANISM; DRUG RESPONSE; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; RACE DIFFERENCE; SEX DIFFERENCE; SOCIAL STATUS; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; RISK FACTORS;

EID: 81255149479     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-011-0221-2     Document Type: Article

References (37)

1. JA Lardizabal PC Deedwania 2010 Benefits of statin therapy and compliance in high risk cardiovascular patients Vasc Health Risk Manag 6 843 53 20957130 1:CAS:528:DC%2BC3cXht1WksrfN
2. CW Weart RJ Hogan 2011 Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy Expert Opin Pharmacother 12 1 99 117 21108580 10.1517/14656566.2010.516747 1:CAS:528:DC%2BC3cXhsFKqurnK
3. SE Nissen SJ Nicholls I Sipahi, et al. 2006 Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 295 13 1556 65 16533939 10.1001/jama.295.13.jpc60002 1:CAS:528: DC%2BD28Xjt12itrc%3D
4. L Osterberg T Blaschke 2005 Adherence to medication NEJM 353 5 487 97 16079372 10.1056/NEJMra050100 1:CAS:528:DC%2BD2MXntVCisL0%3D
5. KE Lutfey WJ Wishner 1999 Beyond "compliance" is "adherence". Improving the prospect of diabetes care Diabetes Care 22 4 635 9 10189544 10.2337/diacare.22.4.635 1:STN:280:DyaK1M3gsFGnsA%3D%3D
6. P Greenland JS Alpert GA Beller, et al. 2010 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults J Am Coll Cardiol 56 25 e50 103 21144964 10.1016/j.jacc.2010.09.001
7. P Libby 2001 Current concepts of the pathogenesis of the acute coronary syndromes Circulation 104 365 72 11457759 1:CAS:528:DC%2BD3MXlslOmtLc%3D
8. MMWR Morb Mortal Wkly Rep. 2011;60(4):109-14. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol-United States, 1999-2002 and 2005-2008
9. AM Gotto Jr JC LaRosa D Hunninghake, et al. 1990 The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease Circulation 81 1721 33 2184951 10.1161/01.CIR.81.5.1721
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344(8934):1383-9.
11. Bersot TP: Chapter 31. Drug therapy for hypercholesterolemia and dyslipidemia. Goodman and Gilman: The pharmacological basis of therapeutics,12e.McGraw-Hill. 2011.
12. CG Mihos MJ Salas O Santana 2010 The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review Cardiol Rev 18 6 298 304 20926939 10.1097/CRD. 0b013e3181f52a7f
13. CP Cannon E Braunwald CH McCabe DJ Rader JL Rouleau R Belder SV Joyal KA Hill MA Pfeffer AM Skene for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction Investigators 2004 Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 1495 504 15007110 10.1056/NEJMoa040583 1:CAS:528:DC%2BD2cXjtVeqtr8%3D
14. DD Waters GG Schwartz AG Olsson, et al. 2002 Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy Circulation 106 13 1690 5 12270864 10.1161/01.CIR.0000031568.40630.1C 1:CAS:528:DC%2BD38XntVynsbc%3D
15. JC LaRosa SM Grundy DD Waters C Shear P Barter J-C Fruchart AM Gotto H Greten JJP Kastelein J Shepherd NK Wenger the Treating to New Targets Investigators 2005 Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 1425 35 15755765 10.1056/NEJMoa050461 1:CAS:528:DC%2BD2MXjtVWltrw%3D
16. TR Pedersen O Faergeman JJP Kastelein AG Olsson MJ Tikkanen I Holme ML Larsen FS Bendiksen C Lindahl M Szarek J Tsai for the Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group 2005 High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the ideal study: a randomized controlled trial JAMA 294 2437 2445 16287954 10.1001/jama.294.19.2437 1:CAS:528:DC%2BD2MXht1aku7jK
17. PM Ridker E Danielson FAH Fonseca, et al. 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2195 207 18997196 10.1056/NEJMoa0807646 1:CAS:528:DC%2BD1cXhtl2gurnL
18. DM Mann M Woodward P Muntner, et al. 2010 Predictors of nonadherence to statins: a systematic review and meta-analysis Ann Pharmacother 44 9 1410 21 20702755 10.1345/aph.1P150
19. CA Jackevicius M Mamdani JV Tu 2002 Adherence with statin therapy in elderly patients with and without acute coronary syndromes JAMA 288 4 462 7 12132976 10.1001/jama.288.4.462
20. JS Benner RJ Glynn H Mogun, et al. 2002 Long-term persistence in use of statin therapy in elderly patients JAMA 288 4 455 61 12132975 10.1001/jama.288.4.455
21. X Ye CR Gross J Schommer, et al. 2007 Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study Clin Ther 29 12 2748 57 18201593 10.1016/j.clinthera.2007.12.022
22. DC Chan WH Shrank D Cutler 2010 Patient, physician, and payment predictors of statin adherence Med Care 48 3 196 202 19890219 10.1097/MLR.0b013e3181c132ad
23. AH Traylor JA Schmittdiel CS Uratsu, et al. 2010 Adherence to cardiovascular disease medications: does patient-provider race/ethnicity and language concordance matter? J Gen Intern Med 25 11 1172 7 20571929 10.1007/s11606-010-1424-8 When examining the impact of similarities between patients and their physicians, this study demonstrated that African Americans had improved adherence when their physician was also African American. Spanish-speaking patients had similar improved adherence when their physician also spoke Spanish.
24. JN Rasmussen GH Gislason S Rasmussen, et al. 2007 Use of statins and beta-blockers after acute myocardial infarction according to income and education J Epidemiol Community Health 61 12 1091 7 18000133 10.1136/jech.2006.055525
25. LA Donnelly AS Doney AD Morris, et al. 2008 Long-term adherence to statin treatment in diabetes Diabet Med 25 7 850 5 18644071 10.1111/j.1464-5491.2008. 02476.x 1:STN:280:DC%2BD1cvms1Cnsw%3D%3D Adherence to statin therapy is highest amongst those diabetic patients who have additional cardiovascular comorbidity.
26. DG Pittman W Chen SJ Bowlin, et al. 2011 Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations Am J Cardiol 107 11 1662 6 21439533 10.1016/j.amjcard.2011.01.052
27. A Kulik WH Shrank R Levin, et al. 2011 Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization Am J Cardiol 107 10 1409 14 21414595 10.1016/j.amjcard.2011.01.013 In patients who receive coronary revascularization compared to those who are treated with medicines alone, adherence is higher among patients treated with medicines alone. This identifies the need for greater attention to adherence among patients who undergo coronary revascularization.
28. E Bruckert G Hayem S Dejager, et al. 2005 Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study Cardiovasc Drugs Ther 19 6 403 14 16453090 10.1007/s10557-005-5686-z 1:CAS:528:DC%2BD28XhtlGku7w%3D
29. SM Cohen M Kataoka-Yahiro 2010 Provider adherence to clinical guidelines related to lipid-lowering medications Mil Med 175 2 122 6 20180482
30. WB Borden RF Redberg AI Mushlin, et al. 2011 Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention JAMA 305 18 1882 89 21558519 10.1001/jama.2011.601 1:CAS:528:DC%2BC3MXlvFKiu7g%3D
31. MA Brookhart AR Patrick S Schneeweiss 2007 Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use Arch Intern Med 167 8 847 52 17452550 10.1001/archinte.167.8.847
32. •• Daugherty SL, Ho PM, Spertus JA, et al. Association of early follow-up after acute myocardial infarction with higher rates of medication use. Arch Intern Med. 2008;168(5):485-91; discussion 492. Patient follow-up with their physicians early after an MI plays an important role in improving statin adherence. In particular, statin use is best adhered to when the patient follows up with both the primary care physician and the cardiologist.
33. Gibson TB, Mark TL, Axelsen K, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12 Spec no.:SP11-9.
34. •• Helin-Salmivaara A, Korhonen MJ, Alanen T, et al. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland. J Clin Pharm Ther. 2011 Mar 16. Lower out-of-pocket expenses for statins are associated with improved adherence.
35. JJ Ellis SR Erickson JG Stevenson, et al. 2004 Suboptimal statin adherence and discontinuation in primary and secondary prevention populations J Gen Intern Med 19 6 638 45 15209602 10.1111/j.1525-1497.2004.30516.x
36. AK Gehi S Ali B Na MA Whooley 2007 Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study Arch Intern Med 167 16 1798 803 17846400 10.1001/archinte.167. 16.1798
37. M Pladevall LK Williams LA Potts, et al. 2004 Clinical outcomes and adherence to medications measured by claims data in patients with diabetes Diabetes Care 27 12 2800 5 15562188 10.2337/diacare.27.12.2800